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Abstract
Background: Current German or UK package leaflets do not contain an explicit notice that the listing of side
effects does not imply that they are caused by the drug. Causal interpretations by patients and lay people
are frequently observed. The authors examined whether health professionals understand that there is not
necessarily a causal relation between drug intake and the frequency of side effects and whether adding
placebo comparison improves understanding.
Methods: Exploratory survey consisting of eight assessments, each containing 2–6 survey items, and focus
groups with one survey sample using questionnaires on adverse reactions in standard package leaflets and
modified package leaflets supplemented with placebo comparison. Participants were convenience samples of
379 health professionals including 153 physicians (80 gynaecologists, 124 diabetes experts - physicians, nurses,
and others, 39 medical students in their last year at university, 49 first year health science and education
students with completed vocational training and professional experience in various health care professions
and 87 pharmacists/pharmacy students). They were asked to rate how often the different adverse reactions
listed were caused by drug intake.
All surveys were carried out within university seminars and postgraduate lectures from April 2014 to June
2015 in Germany. Response rate was 86 % or higher.
Results: Without placebo comparison, the majority of participants responded that the drug causes adverse
reactions with the frequency given in the package leaflet or even more often (95 % of health science
students, 100 % of medical students, 60 to 80 % of physicians and 66 % of pharmacists/pharmacy students).
Simply adding placebo comparison in a table did not prevent misunderstanding. Analysis of focus groups
with health science students supported the lack of understanding.
Conclusions: In the present surveys, health professionals had major difficulties understanding frequency
information on side effects in package leaflets. The great majority erroneously implied a causal relation
between drug intake and the frequency of side effects, even though most side effects listed are symptoms
commonly experienced in daily life.
Keywords: Drug-related side effects and adverse reactions, Placebo, Drug labelling, Risk communication,
Consumer health education
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Background
At a recent national meeting of an influential women’s
health group in Germany, the key participant of a prom-
inent panel discussion on “The Pill” explained why she
had stopped taking her oral contraceptives. Studying the
package leaflet she was worried by the reported effects
of the pill on her psyche. She reasoned: “More than 1 in
10 experience depression due to the pill” and “10 % of
women are suffering from tiredness and weakness” [1].
She undoubtedly interpreted the listed frequencies of
symptoms as causally related to the oral contraceptive.
We have been observing similar misconceptions among
students in health sciences and education. A systematic
review of the literature revealed that so far, no research
has been published on causal interpretation of adverse
events in package leaflets by patients, laypeople or health
professionals.
German or UK package leaflets do not contain an expli-
cit notice that side effects listed are not necessarily caused
by the drug. However, for estimating a drug’s risk profile it
is essential to understand that most side effects can also
occur when the specific compound is not taken [2].
There is good evidence that risks and benefits of drugs
are over- or underestimated if data on placebo is missing
[3, 4]. Therefore, Schwartz et al. developed “drug facts
boxes” to communicate drug effects in comparison to
placebo. They demonstrated that this format is easily
understood by patients, even those with lower education
[5]. In the US, some package leaflets already contain
placebo information, if the incidence of the adverse reac-
tion is 2 % or more and higher than in the placebo
group. Due to the lack of placebo data in German or UK
package leaflets drawing conclusions on causality is
impossible.
There are no studies explicitly analyzing if health care
professionals assume a causal relation for every adverse
reaction listed in the package leaflet. One would expect
that at least health professionals can correctly interpret
drug information. Therefore, the aim of our study was to
investigate health professionals’ understanding of the
adverse events section of the package leaflet as currently
used in countries like Germany or the UK. Secondly, we
wanted to evaluate whether understanding can be
improved by the additional presentation of placebo data.
Methods
Exploratory survey consisting of eight assessments with
6 convenience samples of 22 to 124 participants from
various health professions including physicians, nurses
and other health care professionals, medical students,
pharmacists, pharmacy students and students in health
sciences and education. A master’s degree in health
sciences and education is required to teach at schools
for vocational health care professions. Since vocational
health care training is required to be admitted to this
course, these students have gained professional experi-
ence in various health care professions e.g. nursing or
doctor’s assistant.
Assessments consisted of a standard or modified
package leaflet (mainly excerpts) and a questionnaire.
Modified package leaflets contained placebo compari-
son data. Package leaflets were chosen according to the
expected interest of the groups. For further details see
Additional file 1, I–VIII.
Group 1
Twenty-two Year One/second semester students in
health sciences and education at Hamburg University.
20/22 (91 %) were female, therefore a package leaflet of
combined oral contraceptives was chosen. This group
received standard package leaflets only. Answers were
given as free text. Two assessments with variations in
framing the questions were carried out in April 2014 at
1 week intervals during a seminar on methods of clinical
and epidemiological research by one of the authors (IM).
Changes in group size are due to students being absent
from the seminar.
Group 2
Twenty-seven Year One/first semester students in health
sciences and education at Hamburg University; 25/27
(93 %) were female. As a first assessment they received
standard package leaflets, and during a second assess-
ment 1 week later they were presented modified package
leaflets of combined oral contraceptives. For this group
the questionnaire was supplemented with a question on
venous thromboembolism. The presentation of this ad-
verse reaction in package leaflets already includes com-
parative risk data and was therefore used as a control
question. Answers were given as free text. Both assess-
ments were carried out in October 2014 during a sem-
inar in pharmacology held by one of the authors (VM).
Changes in group size are due to students being absent
from the seminar.
Due to unexpected responses to the modified package
leaflet indicating insufficient understanding of compara-
tive data, in depth focus group interviews were conducted
with this group a few weeks later on the modified package
leaflet containing placebo comparison. The interviews
were carried out in four groups of six to seven students
using the Think Aloud Test [6]. All interviews were re-
corded on a voice recorder and transcribed. Analysis was
carried out according to Mayring [7].
Group 3
Eighty gynaecologists at a conference organized by the
“German-Turkish Association of Gynaecologists” in the
city of Stuttgart in October 2014. This group received
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only standard package leaflets of combined oral contra-
ceptives. Questions were presented as multiple choice
format and answers were given via an electronic response
system.
Group 4
One hundred twenty-four health care professionals during
a post-graduate training course in clinical diabetology.
Most of them were physicians (59 %) or other health care
professionals (e.g. diabetes nurses, 36 %) (5 % others). The
training course took place at Friedrich-Schiller-University,
Jena, in November 2014. Questions were presented as
multiple choice format and answers were given via an
electronic response system.
Group 5
Thirty-nine medical students in their last year at
university (fifth year), Martin Luther University, Halle-
Wittenberg, Germany. The same standard and modified
package leaflet of statins was used for this group as for
group 4. Questions were presented as multiple choice for-
mat and answers were given in writing. All assessments
were carried out in November-December 2014.
Group 6
Pharmacy group (14 pharmacists, 61 pharmacy students
and trainee pharmacists, two other health professionals
and ten others) during “Pharmacy day” in June 2015 at
the Institute of Pharmacy, Hamburg University. They
were presented a standard and a modified package leaflet
on statins (Additional file 1, VII). In comparison to
group 4 and 5, this time the placebo comparison data
were supplemented with p-values. P-values clearly indi-
cated that the differences in the frequency of side effects
between statins and placebo were not statistically signifi-
cant. Questions were presented as multiple choice for-
mat and answers were given via an electronic response
system.
Groups 3–6 were asked whether they know or use the
Cochrane Library as an indicator of their competencies
in evidence-based medicine and risk knowledge. Group
1 had recently been introduced to the Cochrane Library,
Group 2 not yet.
In all groups, care was taken to allow for sufficient
time and a trustful ambience during the assessments.
Participants were invited to support our research project
to help improve understandability of package leaflets.
Questions were read out loudly with particular emphasis
on the word “cause”.
We focused on adverse reactions that seem to occur
with a comparable frequency without drug intake –
depression/mood disorder and weight gain for oral con-
traceptives and myalgia/muscle pain for statins. The
underlying evidence was taken from two Cochrane
reviews [8, 9] and a systematic review [10]. Where
Cochrane data were not available we performed a
supplementary search for placebo-controlled trials.
In assessments using standard package leaflets,
participants were asked to rate how often the drug
causes specific symptoms and to estimate how often
these symptoms occur without taking the drug (for
exact wording see Additional file 1, I–III and V–VII
and Tables 1 and 2).
In order to find out whether adding the frequency
with which specific symptoms occur under placebo
treatment [11] would improve understanding we sup-
plemented standard package leaflet information by a
table displaying frequencies of adverse reactions under
drug treatment in comparison to placebo treatment.
All frequencies were given as percentages only – a
format usually well understood [12].
Participants were considered to be misunderstanding
the package leaflet when reported values were equal to
the frequency in the package leaflet or higher. Answers
were accepted if they were “none” or at least of a lower
frequency than stated in the package leaflet. In multiple
choice questions, missing answers could be an answer as
well as a sign of non-participation.
According to the literature, a causal relationship
between the chosen drugs and the selected adverse reac-
tions does not exist [8, 9, 11]. Still, the underlying
evidence base is insufficient. A causal relation can there-
fore neither be confirmed nor completely ruled out.
Ethics statement
Our survey complied with the Helsinki Declaration.
According to the code of medical ethics for Hamburg,
obtaining formal ethical approval for this study was not
required. No medical interventions were involved and
the impact of the questionnaires on daily life was consid-
ered minor and thus the welfare and rights of the partic-
ipants were protected. Participants were free to answer
the questions or not. Students were told that the survey
was anonymous and had no impact on the grading of
the seminar. The survey was conducted according to
German data privacy regulations.
Results
Standard package leaflet
When asked how often the oral contraceptive causes
depression or weight gain, 22/22 (100 %) (depression)
and 20/22 (91 %) (weight gain) health science students
(group 1) stated the frequency of occurrence given in the
package leaflet (Table 1/question 1). Slightly rephrasing the
question resulted in identical answers 1 week later (Table 1/
question 2). Of the second group of health science students
(group 2) who had just entered university, 10/25 (40 %)
(mood disorder and weight gain) answered within the
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frequency given in the package leaflet, whereas 10 to 11/25
(40–44 %) even replied these side effects were caused more
often by the oral contraceptive than the frequency listed in
the package leaflet (Table 1/question 2). None of them
replied that questions on causality could not be answered
based on the information provided. However, 18, 21 and 22
of the 25 students were able to correctly report the frequen-
cies of venous thrombosis as reported in three scenarios in
the package leaflet (see Additional file 1, III).
Similarly, 56/80 (70 %) gynaecologists (group 3) rated
the frequency given in the package leaflet and 7/80 (9 %)
even higher (Table 1/question 3). Only 11/80 (14 %) par-
ticipants responded with a lower frequency (6/80 (7 %) no
response).
When asked how many women not taking any oral
contraceptives experience the symptoms depression and
weight gain, 12/21 (57 %) (group 1, Table 1/question 4)
believed that these symptoms must occur less often
Table 1 Responses to questionnaire on standard format package leaflet (oral contraceptives without placebo comparison)
Extract of questionnaire
Common side effects (more than 1 in 100 people who take Lovelle® are affected):
• Depression or mood disorder
• Headache
• Stomach problems, such as nausea
• Breast problems, such as painful or tender breasts
• Weight gain
Question 1: How often does the intake of this oral contraceptive cause (1) depression or mood disorder (2) weight gain?a
Responses (No) None Lower frequency than
listed in package leaflet
Same frequency as
listed in package leaflet
Higher frequency than
listed in package leaflet
No response
Format free text
Group 1 (n = 22) Health science students (1): 0 (1): 0 (1): 22 (100 %) (1): 0 (1): 0
(2): 0 (2): 0 (2): 20 (91 %) (2): 0 (2): 2 (9 %)
Question 2: If 100 women take this oral contraceptive – in how many women does the intake of this oral contraceptive cause (1) depression or
mood disorder (2) weight gain?b
Responses (No) None Lower frequency than
listed in package leaflet
Same frequency as
listed in package leaflet
Higher frequency
than listed in package leaflet
No response
Format free text
Group 1 (n= 21) Health science students (1): 0 (1): 0 (1): 21 (100 %) (1): 0 (1): 0
(2): 0 (2): 0 (2): 21 (100 %) (2): 0 (2): 0
Group 2 (n = 25) Health science students (1): 0 (1): 4 (16 %) (1): 10 (40 %) (1): 10 (40 %) (1): 1 (4 %)
(2): 0 (2): 3 (12 %) (2): 10 (40 %) (2): 11 (44 %) (2): 1 (4 %)
Question 3: If 100 women take this oral contraceptive – in how many women does the intake of this oral contraceptive cause (1) depression or
mood disorder?b
Responses (No) 0 1 >1 >10 No response
Format multiple choice
Group 3 (n = 80) Gynaecologists (1): 0 (1): 11 (14 %) (1): 56 (70 %) (1): 7 (9 %) (1): 6 (7 %)
Question 4: If 100 women do not take an oral contraceptive – in how many of them does (1) depression or mood disorder (2) weight gain occur?c
Responses (No) None Lower frequency than
listed in package leaflet
Same frequency as
listed in package leaflet
Higher frequency than
listed in package leaflet
No response
Format free text
Group 1 (n = 21) Health science students (1): 0 (1): 12 (57 %) (1): 1 (5 %) (1): 1 (5 %) (1): 7 (33 %)
(2): 0 (2): 12 (57 %) (2): 1 (5 %) (2): 1 (5 %) (2): 7 (33 %)
aPossible answers: Since the exact value cannot be known from the information provided, any value lower than given in the package leaflet would be accepted.
The frequency given in the package leaflet or higher would definitely be wrong. Due to it being free text, missing responses were seen as a sign
of non-participation
bSince the exact value cannot be known from the information provided, any value lower than given in the package leaflet including no response would be
accepted. The frequency given in the package leaflet or higher would definitely be wrong
cPossible answers: Since the exact value cannot be known from the information provided, any value except “none” or higher values than listed in the package
leaflet would be accepted. Due to it being free text, missing responses were seen as a sign of non-participation
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than in women taking oral contraceptives,”otherwise
it would not be listed as side effect in the package
leaflet“.
Comparable results were obtained using the original
statin package leaflet; 75/124 (60 %) participants of
the post-graduate training in clinical diabetology
(group 4) replied that the statin causes myalgia or
muscle pain with the given frequency of occurrence
listed in the package leaflet (Table 2/question 1, exact
data lost due to technical problems, but the value
was confirmed independently by two other lecturers).
Results were similar for fifth year medical students
(group 5) and the pharmacy group (group 6). None
of the medical students and only 11/87 (12 %) of the
pharmacy group responded a value lower than listed
in the package leaflet (Table 2/question 1). 24/39
(62 %) of the medical students and 18/87 (21 %) of
the pharmacy group stated that muscle pain would
not occur in any patient not taking statins (Table 2/
question 2).
Modified package leaflet
Adding data on the occurrence of side effects in the pla-
cebo group to the package leaflet on oral contraceptives
didn’t have a substantial effect. None of the health
science students (group 2) realised that there was no
difference between the groups (Table 3/question 1).
Analysis of the focus group interviews revealed that
the students had difficulties understanding the slightly
more scientific data. Most students were unable to make
use of the frequency of occurrence presented only as
percentages. Furthermore, being given the total number
of patients participating in the study greatly confused
them. However, they were able to understand placebo
data to be roughly comparable to people not on medica-
tion and to find the corresponding values in the package
leaflet (Table 3/question 2).
When the participants of the post-graduate training
in clinical diabetology (group 4) were presented with
the statin comparison to placebo data, still 65/124
(52 %) answered the frequency as originally given in
Table 2 Responses to questionnaire on standard format package leaflet (statins without placebo comparison)
Extract of questionnaire
CRESTOR® 10 mg film-coated tablets








Question 1: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a
Responses (No) 0 1 >1 >10 No response
Format multiple choice
Group 4 (n = 124) Diabetes experts 75b (60 %)
Group 5 (n = 39) Medical students 0 0 37 (95 %) 2 (5 %) 0
Group 6 (n = 87) Pharmacy group 2 (2 %) 9 (10 %) 57 (66 %) 19 (22 %) 0
Question 2: If 100 patients do not take this statin – in how many of them does muscle pain occur?c
Responses (No) 0 1 >1 >10 No response
Format multiple choice
Group 4 (n = 124) Diabetes experts 16 (13 %) 11 (9 %) 64 (51 %) 17 (14 %) 16 (13 %)
Group 5 (n = 39) Medical students 24 (62 %) 5 (13 %) 4 (10 %) 5 (13 %) 1 (2 %)
Group 6 (n = 87) Pharmacy group 18 (21 %) 8 (9 %) 35 (40 %) 25 (29 %) 1 (1 %)
aSince the exact value cannot be known from the information provided, any value lower than given in the package leaflet including no response would be
accepted. The frequency given in the package leaflet or higher would definitely be wrong
bExact data lost due to technical problems, but the value was confirmed independently by two other lecturers
cPossible answers: Since the exact value cannot be known from the information provided, any value except “none” and “more than 10” including no response
would be accepted
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the package leaflet and 9/124 (7 %) even higher. Only
16/124 (13 %) realised that there was no difference
(Table 4).
Despite the placebo comparison, at least 26/39 (67 %)
medical students (group 5) were unable to see that there
is no difference in occurrence between the two groups
(Table 4). Results in the pharmacy group (group 6) were
similar (Table 5), although they had been provided with
the corresponding p-values indicating non-significance:
77/87 (88 %) did not see that muscle pain occurred as
often in the placebo group as in the statin group.
Discussion
Our survey indicates that various health care profes-
sionals have major difficulties understanding frequency
information on adverse events in package leaflets. The
great majority erroneously implied a causal relation be-
tween drug intake and the rate with which the listed
Table 3 Responses to questionnaire on modified package leaflet (oral contraceptives with placebo comparison)
Extract of questionnaire
Frequency of side effects that were reported in a clinical trial on norgestimate/ ethinylestradiol (e.g. Amicette®) with 462 participants:
Norgestimate/ethinylestradiol Placebo
Headache 18.4 % 20.5 %
Painful or unusual periods 10.1 % 9.0 %
Weight gain 2.2 % 2.1 %
Question 1: If 100 women take this oral contraceptive – in how many women does the intake of this oral contraceptive cause (1) headache (2)
painful or unusual periods (3) weight gain?a
Responses (No) None Lower frequency than
listed in package leaflet
Same frequency as listed
in package leaflet
Higher frequency than
listed in package leaflet
No response
Format free text
Group 2 (n = 27) Health science students 0 (1): 7 (26 %) (1): 12 (44 %) (1): 3 (11 %) (1): 5 (19 %)
0 (2): 6 (22 %) (2): 13 (48 %) (2): 6 (22 %) (2): 2 (7 %)
0 (3): 7 (26 %) (3): 13 (48 %) (3): 2 (7 %) (3): 5 (19 %)
Question 2: If 100 women do not take an oral contraceptive – in how many of them does (1) headache (2) painful or unusual periods (3) weight
gain occur?b
Responses (No) None Lower frequency than
listed in package leaflet
Same frequency as listed
in package leaflet
Higher frequency than
listed in package leaflet
No response
Format free text
Group 2 (n = 27) Health science students 0 (1): 7 (26 %) (1): 12 (44 %) (1): 3 (11 %) (1): 5 (19 %)
0 (2): 6 (22 %) (2): 13 (48 %) (2): 4 (15 %) (2): 4 (15 %)
0 (3): 6 (22 %) (3): 13 (48 %) (3): 3 (11 %) (3): 5 (19 %)
aPossible answers: “None” is the correct answer. Since we have not provided any p-values for this table and therefore statistical significance cannot be identified,
“1” would also be correct in part (2) and accepted in (3). Due to it being free text, missing responses were seen as a sign of non-participation
bPossible answers: Whether women not taking oral contraceptives are equal to women taking placebo depends on placebo and nocebo effects. Therefore, all
answers except “none” were accepted. Due to it being free text, missing responses were seen as a sign of non-participation
Table 4 Responses to questionnaire on modified package leaflet (statins with placebo comparison)
Extract of questionnaire
Frequency of side effects that were reported in clinical trials on statins with 37,938 patients (excerpt, Cochrane review 2013):
Statins Placebo
Muscle pain 9.5 % 9.2 %
Question: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a
Responses (No) 0 1 >1 >10 No response
Format multiple choice
Group 4 (n = 124) Diabetes experts 16 (13 %) 17 (14 %) 65 (52 %) 9 (7 %) 17 (14 %)
Group 5 (n = 39) Medical students 6 (15 %) 6 (15 %) 22 (57 %) 4 (10 %) 1 (3 %)
aPossible answers: “0” would be the correct answer. Since we have not provided any p-values for this table and therefore statistical significance cannot be
identified, “1” would also be accepted
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symptoms occur. Supplementation with placebo data did
not prevent misinterpretation.
Package leaflets have always been a target of criticism
and subject to change. Three decades ago, they were still
optional, used medical terminology and contained only
verbal descriptors to classify adverse reactions [13, 14].
Nowadays, package leaflets are mandatory, more user-
friendly, and numerical frequencies have become an
obligatory supplement to verbal descriptors [15, 16].
Placebo information is usually not included, although
information on comparators has been supplemented for
selected risks. For example, in an increasing number of
package inserts of oral contraceptives, thromboembolic
risk is now communicated for women who take this pill,
those who do not take it or take a pill with a different
component, and pregnant women.
So far, most research on patients’ understanding of the
reported adverse events has been done on direct-to-
consumer advertising. Davis [17] had analysed potential
customers’ preferences as to whether placebo data
should be presented in drug advertisements. Of the 364
participants in the survey, 52.6 % preferred the inclusion
of placebo-group incidence levels, whereas 37.5 % did
not, 9.9 % had no preferences. However, wanting the
information does not necessarily mean that the informa-
tion is understood. O’Donoghue [4] had used placebo
comparison for quantifying only benefit information in
drug advertisements. Therefore the results may not be
transferable to risk information. They found that pla-
cebo rate information resulted for some participants
in more accurate benefit perceptions whereas benefit
was greatly overestimated when placebo information
was missing.
Tan et al. pointed out that the “excessive, inconsistent
and poorly presented information about adverse drug
reactions” [2] has the potential to do harm. Most adverse
drug reactions listed in package leaflets and other
sources of drug information are unspecific symptoms
commonly experienced in daily life. Patients assuming a
causal relation between drug intake and every adverse
reaction listed in the package leaflet may substantially
overestimate harm caused by the drug and thus decide
against intake for the wrong reason [2]. Pfistermeister et
al. drew comparable conclusions. Furthermore, they
found that up to 40 % of UK and German package
inserts contain “at least one potentially conflicting pair
of adverse reactions”, i.e. contradictory symptoms like
increased and decreased appetite [18].
In our study, just presenting percentages of adverse
events during drug treatment compared to placebo
treatment in a table format did not enable health care
professionals to question the assumed causal relation-
ship between drug intake and the rate of occurrence
of listed side effects. Even physicians and medical students
seem to have great difficulties understanding placebo
comparisons.
Difficulties seem to be related to understanding and
interpreting data, not to finding data within the package
leaflet or reading tables. Tables that demand no particu-
lar risk literacy and additional interpretation could be
subject of further research.
Various factors and the use of convenience samples
itself can adversely interfere with the performance of
surveys leading to biased findings. Therefore, we took
great care to offer a trustful ambience and the necessary
time frame. Participation rates were high, and all 6
heterogeneous survey groups gave similar responses. Dif-
ferent framing of questions gave identical responses. Not-
ably, the majority of health science students correctly
identified comparative risk information for thrombo-
embolic events from the package leaflets of oral contra-
ceptives. Analysis of the focus group interviews supported
the overall findings indicating a lack of understanding of
placebo data. Therefore, we are confident that the results
of our survey are valid.
Our study has limitations. The survey has an explora-
tive design. It was carried out in Germany including
convenience samples. Only a small proportion of
Table 5 Responses to questionnaire on modified package leaflet supplemented with p-values (statins with placebo comparison)
Extract of questionnaire
Frequency of muscle pain that was reported in clinical trials on statins:
Statins Placebo p-value
Cochrane 2013 N = 37,938, primary prevention 9.5 % 9.2 % 0.40
Finegold 2014 N = 46,262, primary prevention 7.9 % 7.6 % 0.407
Finegold 2014 N = 37,618, secondary prevention 4.8 % 4.6 % 0.558
Question: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a
Responses (No) 0 1 >1 >10 No response
Format multiple choice
Group 6 (n = 87) Pharmacy group 10 (12 %) 12 (14 %) 48 (55 %) 14 (16 %) 3 (3 %)
aPossible answers: “0” would be the correct answer
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participants indicated that they used the Cochrane
Library, a larger group didn’t even know it (Additional
file 1, VIII). Therefore, competencies in evidence-based
medicine and risk knowledge might be higher in other
countries possibly also facilitating better understanding
of package leaflets. In order to achieve high participation
rates we refrained from collecting further demographic
information or assessing numeracy.
Finally, in order to attract the attention of our survey
participants, the questions on oral contraceptives and
statins dealt with side effects that are commonly attrib-
uted to the drug, but where evidence does not unam-
biguously support a causal relationship. In fact, there
were no significant differences in the drug and placebo
comparisons used in our examples. We are aware of the
controversies surrounding myalgia and muscle pain dur-
ing statin treatment [19], and it is difficult to identify
studies comparing oral contraceptives with placebo
reporting statistically significant differences in side
effects. We could not identify evidence on there being a
causal relation between the two [8, 11]. However, it
might also be due to insufficient reporting of adverse
events in clinical trials [20]. Despite this uncertainty, it is
improbable that depression and mood disorder during
oral contraceptive use are caused with a frequency of 1–
10 % as listed in most package leaflets. The focus of our
study was to analyse understanding. Therefore, the limi-
tations related to the evidence base used in our exam-
ples can be neglected - an approach equally used by
Schwartz et al. [5] to evaluate the drug-facts-boxes.
Despite the limitations of this explorative study, we
doubt that investigations including samples more repre-
sentative for various health care professionals would
provide different results. Rather, the focus of further re-
search should be the development of a format informing
about side effects that can easily be understood.
Conclusion
Currently, the package leaflet is first and foremost a
legal document rather than an instrument to inform
patients – the information provided in the package
leaflet is regulated by law [21] and the pharmaceutical
company can be sued if damage occurred due to a
package leaflet not being on the current state of med-
ical knowledge [22]. It is therefore not surprising that
pharmaceutical companies add side effects to the
package leaflet whenever there is the slightest possi-
bility for a causal relation. Still, our analysis shows
that even the majority of physicians and other health
care professionals assume a causal relation between
drug intake and the side effects listed in the package
leaflet and therefore don’t understand the information
provided. Thus, it is improbable that they inform patients
appropriately on the risk of adverse events due to drug
administration. Informed decision-making is then impos-
sible. Although we acknowledge that package leaflets do
not need to and cannot be a decision aid, the information
provided must be understandable. Other ways of present-
ing data on adverse events have to be found [23] – de-
manding quite a balancing act between legal requirements
and understandable patient information.
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